Observational studyJournal of neuro-oncology2025
Integrating a novel tablet-based digital neurocognitive assessment tool in brain metastases patients.
Observational study in Journal of neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05504681 (Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Integration of Neurocognitive Biomarkers Into a Neuro-Oncology Clinic
Who cites it
2 citing papers in PubMed.
- Feasibility and utility of a tablet-based digital neurocognitive assessment following radiosurgery for brain metastases.Scientific reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
purposePatients with brain metastasis frequently exhibit baseline neurocognitive decline (NCD), which can be further exacerbated by CNS-directed interventions. Despite efforts to measure and preserve neurocognitive function (NCF), the practicality of traditional methods remains a concern. As a contemporary alternative, this study evaluates the feasibility and patient feedback of a novel digital neurocognitive assessment (NCA) tool.
methodsAdult patients undergoing stereotactic radiosurgery (SRS), fractionated SRS (FSRS), or whole-brain radiotherapy (WBRT) from December 2021 to March 2024 were enrolled onto a prospective registry (NCT05504681), which formed the basis for this work. The multi-dimensional, multi-language digital NCA battery was administered at baseline and follow-up, and a feedback survey was collected to assess the tool's usability and patient satisfaction.
resultsA "high risk" cohort of 74 patients with brain metastases and a "low risk" cohort of 14 patients with small benign extra-axial tumors were evaluated. The high risk cohort had higher rates of NCD compared to the low risk cohort (36.5% vs. 7.1%, p = 0.032); driven by patients treated with WBRT vs. SRS/FSRS (73.3% vs. 27.1%, p = 0.001). Notably, 50.0% completed the NCAs in their native language (non-English). Patient feedback indicated that 94% found the NCAs easy to understand, 96% found it easy to use, and 74% found it relevant to their care.
conclusionThis multi-dimensional, multi-language tablet-based NCA tool demonstrated feasibility and patient acceptance in a diverse patient population as well as the ability to discriminate NCD among patients treated with SRS/FSRS vs. WBRT. This approach shows promise for broader implementation, warranting further validation to confirm its efficacy.
Indexed as
Identifiers
40261558What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.